Transgene and NEC present the first signs of clinical benefit of their individualized cancer vaccine, TG4050, in head and neck cancers at the American Association for Cancer Research (AACR) in San Diego (USA).

New Phase I immunological data confirm the strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.

All treated patients are still in remission after a median follow-up of 18.6 months. The Phase II clinical trial will start in the coming weeks.

TG4050 is based on Transgene's myvac® platform and benefits from NEC's Artificial Intelligence (AI) technologies for the identification and prediction of the most immunogenic neoantigens.

Dr. Alessandro Riva, Chairman and CEO of Transgene, commented: "Almost all patients develop a specific immune response against the target antigens we have selected, reinforcing the proof-of-principle of our lead candidate. TG4050 is already demonstrating a beneficial effect in patients with head and neck cancers at high risk of relapse'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.